ILB-2109 / Innolake Biopharma - LARVOL DELTA

A Study of ILB2109 in Patients With Advanced Solid Malignancies (clinicaltrials.gov) - P1 | N=48 | Active, not recruiting | Sponsor: Innolake Biopharm | Recruiting ➔ Active, not recruiting | Trial primary completion date: Aug 2024 ➔ Dec 2024

Enrollment closed • Metastases • Trial primary completion date • Oncology • Solid Tumor

A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies (clinicaltrials.gov) - P1/2 | N=200 | Recruiting | Sponsor: Innolake Biopharm | Not yet recruiting ➔ Recruiting

Enrollment open • Breast Cancer • Cervical Cancer • Endometrial Cancer • Head and Neck Cancer • Hematological Malignancies • Hodgkin Lymphoma • Lung Cancer • Lymphoma • Melanoma • Nasopharyngeal Carcinoma • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Sarcoma • Soft Tissue Sarcoma • Solid Tumor • Triple Negative Breast Cancer • CD68 • CD8 • MSI • PD-L1 • TMB

A Study of ILB2109 in Patients With Advanced Solid Malignancies (clinicaltrials.gov) - P1 | N=48 | Recruiting | Sponsor: Innolake Biopharm | Trial completion date: Jan 2024 ➔ Feb 2025 | Trial primary completion date: Nov 2023 ➔ Aug 2024

Trial completion date • Trial primary completion date • Oncology • Solid Tumor

A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies (clinicaltrials.gov) - P1/2 | N=200 | Not yet recruiting | Sponsor: Innolake Biopharm

New P1/2 trial • Breast Cancer • Cervical Cancer • Endometrial Cancer • Head and Neck Cancer • Hematological Malignancies • Hodgkin Lymphoma • Lung Cancer • Lymphoma • Melanoma • Nasopharyngeal Carcinoma • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Sarcoma • Soft Tissue Sarcoma • Solid Tumor • Triple Negative Breast Cancer

A Study of ILB2109 in Patients With Advanced Solid Malignancies (clinicaltrials.gov) - P1 | N=48 | Recruiting | Sponsor: Innolake Biopharm | Not yet recruiting ➔ Recruiting

Enrollment open • Metastases • Oncology • Solid Tumor

A Study of ILB2109 in Patients With Advanced Solid Malignancies (clinicaltrials.gov) - P1 | N=48 | Not yet recruiting | Sponsor: Innolake Biopharm

New P1 trial • Oncology • Solid Tumor